B+
Bull case
25%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-05-14 · RankAlpha Sentiment Codex
ATAI
AtaiBeckleyFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The post-earnings company update kept the core bull thesis intact: BPL-003 Phase 3 is still slated for Q2 2026, VLS-01 topline is still expected in Q4 2026, and management says the balance sheet funds the company into 2029 [#8-K-2026-05-12] [#10-Q-2026-05-12]. A secondary post-print signal also appears constructive, with StockAnalysis surfacing a Canaccord target increase to $15 from $14 after the release.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -0.9.
What can break
Clinical-stage concentration risk is high: BPL-003 is the lead value driver, while VLS-01 and EMP-01 remain developmental and subject to trial-readout volatility.
Momentum
89
Value
41
Sentiment
28
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.50 · Bull $8.00 · Bear $2.50Analysis 2026-05-14; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $7.91
Why
Momentum89 · Δ7d +4.5
Value41 · Δ7d -0.0
Sentiment28 · Δ7d -0.9
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -0.9.
Contradictions & invalidation
- • Clinical-stage concentration risk is high: BPL-003 is the lead value driver, while VLS-01 and EMP-01 remain developmental and subject to trial-readout volatility.
- • Phase 3 initiation for BPL-003 is only guided to Q2 2026, so any slip beyond the quarter would likely pressure the core thesis.
- • This remains a clinical-stage story with limited commercial proof and no confirmed broad analyst revision set.
Catalyst clock
2026-08-12
BPL-003 Phase 3 initiation remains the key near-term inflection
Lead driver: Sentiment · See AI snapshot
Momentum
89
9% active weight
Current posture
7d trendImproving
Δ7d
+4.5
Δ21d
-6.5
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
28
62% active weight
Current posture
7d trendSoftening
Δ7d
-0.9
Δ21d
+2.1
Why this grade
Composite grade F. Momentum 89.3 / Value 41.2 / Sentiment 27.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-14. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-05-14 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-05-14 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$2.69B
Beta
1.62
Shares Out
370.87M
P/E (TTM) · Derived
-2.5
P/S (TTM)
464.95
P/FCF (TTM) · Derived
-17.04
Rev YoY
+137.0%
EPS YoY
-36.1%
Gross Margin
-5.4%
Op Margin
-3274.3%
Net Debt
-$253.97M
Current Ratio
8.58
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data